Key result
Pharmacological modulation of Glycoprotein VI (GPVI) may provide novel bleeding-free antithrombotic therapies, as GPVI deficiency reduces thrombus formation without causing severe bleeding.
Why the study?
Antiplatelet therapies remain associated with high bleeding risk, driving interest in glycoprotein VI modulation as a potential antithrombotic strategy that minimizes bleeding.
Pharmacological modulation of GPVI may provide a novel antithrombotic therapy that reduces thrombus formation without causing severe bleeding.
Answers are grounded in this paper and cite their sources.
Should not alter antithrombotic strategies; leaves open GPVI modulation as a bleeding-free target pending trials.
Despite significant advances in the treatment of thrombogenic diseases, antiplatelet therapies are still associated with a high bleeding risk. Consequently, potential benefits of preventing thromboembolic events by pharmacological agents need to be balanced with the potential harm of inducing hemorrhage. Glycoprotein VI (GPVI) is a platelet-specific receptor, which plays a crucial role in thrombus formation. GPVI deficiency has been identified in patients who suffer from significant reduction of collagen-induced thrombus formation, with a slight tendency for mild bleeding. However, an isolated GPVI deficiency can reduce thrombus formation while not resulting in severe bleeding. Together, these observations strongly suggest that physiological hemostasis does not require GPVI, but pharmacological GPVI modulation may provide novel "bleeding-free" antithrombotic therapies. In this review, we discuss recent findings regarding the biological role of GPVI in platelet-related disorders and highlight the efforts to develop potential therapeutic strategies based on its structure, signaling pathways, and biological effects.
No takes yet. Share an insight, caveat, or question.
Lima et al. (2019) conducted a review in Thrombosis and cardiovascular diseases. Glycoprotein VI (GPVI) inhibitors was evaluated. Pharmacological modulation of Glycoprotein VI (GPVI) may provide novel bleeding-free antithrombotic therapies, as GPVI deficiency reduces thrombus formation without causing severe bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: